Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)
32.21
-0.16 (-0.49%)
Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses on developing, manufacturing, and marketing injectable and inhalation products
The company is dedicated to providing high-quality medicines, particularly in the areas of complex generics and niche products, which include both branded and generic formulations. Amphastar's research and development efforts are geared towards addressing unmet medical needs and improving patient outcomes, with a strong emphasis on innovative therapies and cost-effective solutions in various therapeutic areas. Through its commitment to quality and regulatory standards, Amphastar aims to deliver safe and effective pharmaceuticals to healthcare providers and patients around the world.
Previous Close | 32.37 |
---|---|
Open | 32.22 |
Bid | 31.00 |
Ask | 32.65 |
Day's Range | 31.76 - 32.48 |
52 Week Range | 31.76 - 56.45 |
Volume | 319,637 |
Market Cap | 1.55B |
PE Ratio (TTM) | 10.70 |
EPS (TTM) | 3.0 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 497,159 |
News & Press Releases
![](https://cdn.benzinga.com/files/images/story/2025/02/04/Analysts.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 4, 2025
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
AMPHASTAR PHARMACEUTICALS IN has caught the attention as a great value stock. NASDAQ:AMPH excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Via Chartmill · January 27, 2025
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · January 8, 2025
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
AMPHASTAR PHARMACEUTICALS IN (NASDAQAMPH) appears to be flying under the radar despite its strong fundamentals.
Via Chartmill · January 6, 2025
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · November 26, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024
Via ACCESSWIRE · November 6, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024
Via ACCESSWIRE · August 7, 2024
![](https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp)
AMPHASTAR PHARMACEUTICALS IN (NASDAQAMPH) may be suited for growth investing, we'll explore why in this article.
Via Chartmill · June 5, 2024
![](https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp)
AMPHASTAR PHARMACEUTICALS IN (NASDAQAMPH) showing high EPS and FCF growth while beating expectations
Via Chartmill · May 15, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · November 13, 2024
![](https://www.investors.com/wp-content/uploads/2023/06/Stock-amphastarpharma-01-shutt.jpg)
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Via Investor's Business Daily · October 15, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/06/Genetic-Research-And-Biotech-Science-Con_1.jpeg?width=1200&height=800&fit=crop)
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.
Via Benzinga · September 6, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · August 28, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 7, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024
Via ACCESSWIRE · May 8, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Via ACCESSWIRE · July 31, 2024
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via InvestorPlace · June 24, 2024
![](https://www.marketbeat.com/logos/articles/med_20240617132312_top-2-small-cap-healthcare-stocks-to-buy-before-ra.jpg)
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each
Via MarketBeat · June 18, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.
Via ACCESSWIRE · June 4, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · June 3, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir® HFA (albuterol sulfate) Inhalation Aerosol.
Via ACCESSWIRE · May 22, 2024
![](https://investorplace.com/wp-content/uploads/2023/03/drug-fraud1600.png)
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Via InvestorPlace · May 16, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQAMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on Wednesday, May 15th, 2024 at 2:20 pm PDT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Via ACCESSWIRE · May 9, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/05/01/Ozempic-and-other-drugs-for-weight-loss.jpeg?width=1200&height=800&fit=crop)
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic competition.
Via Benzinga · May 1, 2024